Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 14/20 | 0.53 |
| ▸ | ATP4B | P51164 | 14/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.53 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.45 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantoprazole SCHEMBL5795111 | 1.00 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL3542 | 1.00 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1560742 | 1.00 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1476428 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL21986309 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1476069 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL7211409 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1477291 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL27913225 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1649650 | 0.99 | ATP4A (0.52) | ATP4AATP4BCYP2C9KDM4ESLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890367-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | Salix Pharmaceuticals, Inc. (US) | 2015-07-08 | — | — | EP | claimed |
| WO-2014032108-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | BORODY THOMAS J (AU) | 2014-03-06 | — | — | WO | claimed |
| US-20200308534-A1 | RECOMBINANT URICASE ENZYME | ALLENA PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20180177831-A9 | Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them | CRESTOVO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170266239-A1 | Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them | CRESTOVO LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150297642-A1 | COMPOSITIONS FOR THE RESTORATION OF A FECAL MICROBIOTA AND METHODS FOR MAKING AND USING THEM | CRESTOVO HOLDINGS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150216806-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | MEDICIS PHARMACEUTICAL CORPORATION | 2015-08-06 | — | — | US | disclosed |
| EP-2890367-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | Salix Pharmaceuticals, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032108-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | BORODY THOMAS J (AU) | 2014-03-06 | — | — | WO | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2008001392-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PANTOPRAZOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | WO | disclosed |
| EP-1572680-A2 | SOLID STATES OF PANTOPRAZOLE SODIUM, KNOWN PANTOPRAZOLE SODIUM HYDRATES, PROCESSES FOR THEIR PREPARATION. | EVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056804-A2 | SOLID STATES OF PANTOPRAZOLE SODIUM, PROCESSES FOR PREPARING THEM AND PROCESSES FOR PREPARING KNOWN PANTOPRAZOLE SODIUM HYDRATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | ATP4A 913/4885ATP4B 1018/4885CYP2C9 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.